Skip to main content

Human Papilloma Virus

Volume 455: debated on Thursday 18 January 2007

To ask the Secretary of State for Health, pursuant to the answer of 12 December 2006, Official Report, columns 1031-2W, on the Human Papilloma Virus vaccination, what the Joint Committee on Vaccination and Immunisation’s Subgroup on the Human Papilloma Virus will discuss when it meets on 28 February; and what further evidence the subgroup is awaiting. (116509)

The Joint Committee on Vaccination and Immunisation subgroup will discuss, based on new information presented at the meeting, the most appropriate age for vaccination; whether there is an advantage in offering the vaccine to boys as well as girls; and the evidence on a vaccination catch-up programme.

The subgroup is examining the health benefits and cost effectiveness of introducing a Human Papilloma Virus vaccine, based on United Kingdom data. In particular, UK data are required on age-specific HPV infection rates by HPV type and single years of life for females aged 11 to 29 years.